| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
We analyzed 406 Japanese patients with lamivudine-refractory chronic hepatitis B treated with lamivudine plus adefovir dipivoxil combination therapy. Substitutions associated with multidrug resistance were identified in 11 patients (2.7%) at baseline, and in 12 patients (3%) during lamivudine plus adefovir dipivoxil therapy. Moreover, we analyzed naïve 976 patients treated entecavir monotherapy. Substitutions associated with entecavir resistance were identified in 9 patients (1%) during entecavir monotherapy. Moreover, these 44 patients with multidrug resistance received tenofovir disoproxil fumarate (TDF) therapy. Ratio of patients with undetectable serum HBV DNA levels during TDF therapy was 67% and 87% at years 1 and 2, respectively. However, viral breakthrough occurred in 2 patients during TDF therapy. Where indicated, HBV DNA and virological analysis should be carefully monitored.
|
